Yes, and yet you do hear from the same people the same goal that we're trying to advance, which is to make sure you have good continuous oversight; then you're picking up the really important safety points. It means not overdoing it in therapies that don't require heightened surveillance, but moving it to models where we really do need good, strong surveillance, very active surveillance.
I'm sure Dr. Carleton could talk about that further.